Sehhoon Park

1.9k total citations
68 papers, 895 citations indexed

About

Sehhoon Park is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Sehhoon Park has authored 68 papers receiving a total of 895 indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Pulmonary and Respiratory Medicine, 46 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in Sehhoon Park's work include Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (21 papers) and Cancer Genomics and Diagnostics (16 papers). Sehhoon Park is often cited by papers focused on Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (21 papers) and Cancer Genomics and Diagnostics (16 papers). Sehhoon Park collaborates with scholars based in South Korea, United States and United Kingdom. Sehhoon Park's co-authors include Se‐Hoon Lee, Myung‐Ju Ahn, Jin Seok Ahn, Jong‐Mu Sun, Keunchil Park, Hyun Ae Jung, Yoon‐La Choi, Joungho Han, Tae Min Kim and Bhumsuk Keam and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Sehhoon Park

63 papers receiving 884 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sehhoon Park South Korea	18	601	543	229	203	95	68	895
Yasir Y. Elamin United States	16	518 0.9×	595 1.1×	164 0.7×	284 1.4×	127 1.3×	68	968
Álvaro Taus Spain	18	408 0.7×	540 1.0×	227 1.0×	223 1.1×	82 0.9×	63	874
Xinmin Yu China	18	704 1.2×	746 1.4×	217 0.9×	193 1.0×	112 1.2×	48	1.1k
Tejas Patil United States	16	624 1.0×	544 1.0×	161 0.7×	228 1.1×	66 0.7×	67	836
Dengfeng Ren China	11	346 0.6×	535 1.0×	149 0.7×	180 0.9×	105 1.1×	47	825
Youngjoo Lee South Korea	17	472 0.8×	583 1.1×	243 1.1×	256 1.3×	182 1.9×	78	939
Sabrina Rossi Italy	19	403 0.7×	611 1.1×	181 0.8×	155 0.8×	76 0.8×	55	899
Pier Vitale Nuzzo United States	16	500 0.8×	389 0.7×	298 1.3×	382 1.9×	109 1.1×	58	943
Jonas Leichsenring Germany	16	405 0.7×	486 0.9×	348 1.5×	205 1.0×	67 0.7×	32	833
Seung Eun Lee South Korea	19	545 0.9×	475 0.9×	239 1.0×	310 1.5×	186 2.0×	46	1.0k

Countries citing papers authored by Sehhoon Park

Since Specialization

Citations

This map shows the geographic impact of Sehhoon Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sehhoon Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sehhoon Park more than expected).

Fields of papers citing papers by Sehhoon Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sehhoon Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sehhoon Park. The network helps show where Sehhoon Park may publish in the future.

Co-authorship network of co-authors of Sehhoon Park

This figure shows the co-authorship network connecting the top 25 collaborators of Sehhoon Park. A scholar is included among the top collaborators of Sehhoon Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sehhoon Park. Sehhoon Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hwang, Soohyun, Boram Lee, Hye Min Kim, et al.. (2025). Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor. Journal for ImmunoTherapy of Cancer. 13(10). e012374–e012374. 1 indexed citations

Park, Sehhoon, et al.. (2025). Digitally Decoding Heritage: Analyzing the Sellman Tenant House Through HBIM and Digital Documentation Techniques. SHILAP Revista de lepidopterología. 4(1). 10–10.

Kim, Young Saing, Keon Uk Park, Jang Ho Cho, et al.. (2024). Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18. JTO Clinical and Research Reports. 5(12). 100734–100734. 1 indexed citations

Park, Sehhoon, Hyun Ae Jung, Jong‐Mu Sun, et al.. (2024). Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM). Journal of Clinical Oncology. 42(23). 2747–2756. 23 indexed citations

Kim, Hyojin, Seokhwi Kim, Sangjoon Choi, et al.. (2024). Clinical Validation of Artificial Intelligence–Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non–Small Cell Lung Cancer. JCO Precision Oncology. 8(8). e2300556–e2300556. 12 indexed citations

Kang, Danbee, Sehhoon Park, Yoo‐Young Lee, et al.. (2024). Evaluating the effect of a mobile-based symptom monitoring system for improving physical function in patients with cancer during chemotherapy: study protocol for a multicentre randomised controlled trial. BMJ Open. 14(5). e080976–e080976.

Park, Sehhoon, Tae Hee Hong, Soohyun Hwang, et al.. (2024). Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer. EBioMedicine. 102. 105062–105062. 22 indexed citations

Hong, Joo-Hyun, Jiyun Lee, Sehhoon Park, et al.. (2024). Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B. Cancer. 130(9). 1693–1701. 3 indexed citations

Jung, Hyun Ae, Boram Park, Sehhoon Park, et al.. (2024). Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis. Lung Cancer. 190. 107536–107536. 1 indexed citations

10.

Park, Sehhoon. (2023). Dancing with the Surgeon: Neoadjuvant and Adjuvant Immunotherapies from the Medical Oncologist’s Perspective. SHILAP Revista de lepidopterología. 56(2). 67–74. 1 indexed citations

11.

Park, Sehhoon, Yu Jung Kim, Young Joo Min, et al.. (2023). Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer. Cancer. 130(4). 541–552. 15 indexed citations

12.

Yoon, Young Cheol, et al.. (2023). Prognostic significance of body mass index in small‐cell lung cancer: Exploring the relationship with skeletal muscle status. Journal of Cachexia Sarcopenia and Muscle. 14(6). 2939–2947. 4 indexed citations

13.

Jung, Sun-Young, You Jeong Heo, & Sehhoon Park. (2023). High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis. Journal for ImmunoTherapy of Cancer. 11(4). e006454–e006454. 43 indexed citations

14.

Lee, Jiyun, Sehhoon Park, Hyun Ae Jung, et al.. (2023). A phase 2 multicenter study of docetaxel‐PM and trastuzumab‐pkrb combination therapy in recurrent or metastatic salivary gland carcinomas. Cancer. 129(19). 2966–2974. 9 indexed citations

15.

Ku, Bo Mi, Sehhoon Park, Hyun Ae Jung, et al.. (2022). Evaluation of MET alteration in EGFR-mutant non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor from paired biopsy: A retrospective cohort study. SHILAP Revista de lepidopterología. 6(4). 233–242. 1 indexed citations

16.

Park, Sehhoon, Chung Lee, Bo Mi Ku, et al.. (2021). Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer. BMB Reports. 54(7). 386–391. 6 indexed citations

17.

Hong, Tae Hee, Hongui Cha, Joonho Shim, et al.. (2020). Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. Journal for ImmunoTherapy of Cancer. 8(2). e001199–e001199. 10 indexed citations

18.

Park, Sehhoon, Beung‐Chul Ahn, Sung Won Lim, et al.. (2018). Characteristics and Outcome of ROS1-Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice. Journal of Thoracic Oncology. 13(9). 1373–1382. 85 indexed citations

19.

Park, Sehhoon, Seunggyun Ha, Se‐Hoon Lee, et al.. (2018). Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE. 13(1). e0189766–e0189766. 46 indexed citations

20.

Park, Sehhoon, Ji Yeon Kim, Se‐Hoon Lee, et al.. (2017). KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. The Korean Journal of Internal Medicine. 32(3). 514–522. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact